Скачать или смотреть TARGET Biomarker Study

The Biomarkers Consortium’s TARGET Biomarker Study sought to identify a novel multi-marker of cardiovascular disease (CVD) risk in rheumatoid arthritis (RA) patients and assess its responsiveness to treatment with disease-modifying antirheumatic drug (DMARD) therapies. CVD is the leading cause of death in patients with RA, and Researchers postulate that enhanced vascular inflammation leads to accelerated atherosclerosis and increased risk of CVD in RA patients.

The project leveraged a multicenter, randomized clinical trial – treatments Against RA and Effect on FDG PET‐CT (The TARGET Trial) — funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS/NIH). The TARGET Trial used 18-fluoro‐deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) to detect baseline and DMARD‐associated changes in both joint and vascular inflammation in RA patients across two treatment arms: addition of a TNF inhibitor vs. addition of sulfasalazine plus hydroxychloroquine to background MTX (i.e., “triple therapy”) in methotrexate (MTX)-inadequate responders. The companion Biomarkers Consortium Project analyzed serum samples from the NIH TARGET Trial to correlate the changes in proteomic biomarkers with vascular FDG PET-CT scans across the two treatment regimens. The results from this study will also help to identify novel prognostic, predictive, pharmacodynamic and/or surrogate biomarkers for use in trials of CVD risk and RA, thus facilitating the development of new treatments in this disease area.

Learn more: https://fnih.org/our-programs/biomark...